Market capitalization | $1.42b |
Enterprise Value | $866.34m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 20.11 |
P/S ratio (TTM) P/S ratio | 33.02 |
P/B ratio (TTM) P/B ratio | 1.48 |
Revenue growth (TTM) Revenue growth | -16.77% |
Revenue (TTM) Revenue | $43.09m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
30 Analysts have issued a Intellia Therapeutics, Inc. forecast:
30 Analysts have issued a Intellia Therapeutics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 43 43 |
17%
17%
|
|
Gross Profit | 33 33 |
24%
24%
|
|
EBITDA | -528 -528 |
11%
11%
|
EBIT (Operating Income) EBIT | -538 -538 |
11%
11%
|
Net Profit | -522 -522 |
13%
13%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | John Leonard |
Employees | 526 |
Founded | 2014 |
Website | www.intelliatx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.